Effects of grape seed proanthocyanidin extract on pentylenetetrazole-induced kindling and associated cognitive impairment in rats

JUNLI ZHEN, ZHENZHEN QU, HAIBO FANG, LAN FU, YUPENG WU, HONGCHAO WANG, HONGMIN ZANG and WEIPING WANG

Department of Neurology, Key Laboratory of Neurology of Hebei Province, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China

Received February 9, 2014; Accepted May 13, 2014

DOI: 10.3892/ijmm.2014.1796

Abstract. Numerous studies have demonstrated the antioxidant effects of grape seed proanthocyanidin extract (GSPE). The generation of free radicals and the ensuing apoptosis may contribute to the pathogenesis of epilepsy; therefore, in the present study, we examined the effects of GSPE on cognitive impairment and neuronal damage induced by chronic seizures in rats. Seizures were induced by a daily intraperitoneal (i.p.) injection of pentylenetetrazole (PTZ; 35 mg/kg/day, 36 days). Two other groups were treated with GSPE (100 or 200 mg/kg/day, orally) for 24 days and then for 36 days prior to each PTZ injection. After the final PTZ injection, hippocampus-dependent spatial learning was assessed using the Morris water maze (MWM). The rats were then sacrificed for the measurement of hippocampal malondialdehyde (MDA, a measure of lipid peroxidation) and glutathione (GSH, a measure of endogenous antioxidant capacity) levels, and for the expression of pro-apoptotic factors [cytochrome-c (Cyt c), caspase-9 and caspase-3]. The mitochondrial generation of reactive oxygen species (ROS), degree of mitochondrial swelling, neuronal damage and mitochondrial ultrastructure were also examined. Performance in the MWM was markedly impaired by PTZ-induced seizures, as evidenced by longer escape latencies during training and fewer platform crossings during the probe trial. This cognitive decline was accompanied by oxidative stress (MDA accumulation, ROS generation, reduced GSH activity), an increased expression of pro-apoptotic proteins, as well as damage to CA1 pyramidal neurons and the mitochondria. Pre-treatment with GSPE dose-dependently reversed PTZ-induced impaired performance in the MWM, oxidative stress, mitochondrial ROS generation, the expression of pro-apoptotic proteins and neuronal and mitochondrial damage. Thus, GSPE may reverse the hippocampal dysfunction induced by chronic seizures, by reducing oxidative stress and preserving mitochondrial function.

Introduction

Epilepsy is a common, often intractable and occasionally fatal neurological disease. Many of the sequelae of chronic seizures result from excitotoxicity and oxidative stress with ensuing mitochondrial damage and neuronal death (1,2). Although there are numerous anti-epileptic drugs (AEDs) available for the management of seizures, they merely treat symptoms, rather than cure the disease and have side-effects that diminish the quality of life, including cognitive impairment (3,4).

Oxidative stress associated with seizure activity can greatly reduce mitochondrial function and is widely accepted as a contributor to learning and memory deficits resulting from epileptic seizures (5). Compared to other organs, the brain is extremely susceptible to damage by free radicals due to its relatively high levels of oxidative metabolism and comparatively low levels of both free-radical scavenging enzymes and antioxidant molecules (6). Glutathione (GSH) plays an important role in antioxidant defense in mammalian tissues (7,8); it has been shown to prevent ischemia-induced neuronal death and improve memory following an ischemic insult (9). The accumulation of malondialdehyde (MDA), an end product of lipid peroxidation, reflects the extent of oxidative stress and indirectly that of cellular antioxidant capacity (10,11). Mitochondrial oxidative stress and dysfunction not only result from seizures, but may directly contribute to epileptogenesis (12). High concentrations of reactive oxygen species (ROS) cause lipid peroxidation and damage to cell membranes, proteins and mitochondrial DNA (13), which exacerbates mitochondrial dysfunction, reduces mitochondrial energy production (14) and triggers apoptotic cell death through the activation of the caspase-3 pathway (3,15). Hence, exogenous antioxidants may be safe and effective agents for seizure control and the prevention of cognitive decline.

Dietary antioxidants may preserve mitochondrial function and energy metabolism, and have other long-term therapeutic benefits (16). The natural antioxidant, grape seed proanthocyan-
idin extract (GSPE), an extract from red grape seeds containing a variety of phenolic compounds, is widely marketed in China as a dietary supplement with a variety of health benefits. It is water-soluble and can cross the blood-brain barrier more easily than other natural antioxidants, such as quercetin (17) and curcumin (18). In addition, GSPE has demonstrated a wide range of biological effects, including antioxidant (19,20), anti-inflammatory (21,22), anti-mutagenic (23), anti-carcinogenic (24), cardioprotective (25,26) and neuroprotective (27) activities in various experimental models; furthermore, it can effectively reduce ischemia/reperfusion injury (28,29). Moreover, it has been reported to enhance working memory, ameliorate symptoms of Alzheimer's disease (30), and significantly improve cognitive performance across age groups (31). However, little is known about the potential neuroprotective efficacy of GSPE against pentylenetetrazole (PTZ)-induced seizures.

The aim of the present study was to evaluate the protective effects of GSPE against seizure-induced cognitive impairment, oxidative stress caused by mitochondrial damage and neuronal apoptosis mediated by the caspase-3 signaling pathway. Our results revealed that GSPE effectively suppressed oxidative stress and neuronal apoptosis induced by epileptic seizures, and improved cognitive decline in epileptic rats.

Materials and methods

Animals. Ninety male Sprague-Dawley rats (180-200 g) were obtained from the Experimental Animal Center of Hebei Medical University. [Animal licenses: SCXK (Hebei 2008-1-003); animal certification no. 1301020]. The animals were allowed to acclimatize for 1 week prior to the experiments. The animals were housed in groups of 4 per cage in a room that was maintained under standard laboratory conditions (12 h light/dark cycle) and a constant temperature (25±1°C) and humidity (50-60%). They were allowed free access to food and water. All experiments conformed to the National Institutes of Health guidelines for the Care and Use of Laboratory Animals and with the European Communities Council Directive of 24 November 1986 (86/609/EEC). Every effort was made to minimize the number of animals used and their suffering.

Materials. GSPE (purity >98%) was kindly provided by Tianjin Jianfeng Natural Product R&D Co., Ltd. (Tianjin, China). The GABA(A)-receptor antagonist, PTZ (CAS:54-95-5; Sigma, St. Louis, MO, USA), was used as an epileptic kindling to establish a chronic epileptic rat model. The levels of MDA and GSH were measured using ELISA kits (Nanjing Jianfeng Bioengineering Institute, Nanjing, China). Mitochondrial ROS production was measured by flow cytometry (BDFACSAria™ II; BD Biosciences, San Jose, CA, USA) using the oxidation-sensitive fluorescent dye, 2,7’-dichlorodihydrofluorescein diacetate (DCFH-DA, CAS:6883, Sigma). The animal model was established by an intraperitoneal (i.p.) injection of PTZ (35 mg/kg/day) for 36 days. GSPE and 1% PTZ were dissolved in physiological saline prior to the experiments. Drugs were administered between 08:30 and 10:30 a.m. to reduce the effects of circadian rhythms.

Experimental groups and drug administration. The rats were randomly divided into 5 groups: i) a control group (n=16) that received normal saline (vehicle) for 60 days (3.5 ml/kg/day, i.p.); ii) a PTZ group (n=22) that received saline (3.5 ml/kg/day, i.p.) for 24 days followed by PTZ (35 mg/kg/day, i.p.) for 36 days; iii) and iv) the PTZ + GSPE groups (n=18/group) that were treated with GSPE (100 or 200 mg/kg/day, by gavage) for 24 days then pre-treated with the same doses 30 min prior to each PTZ administration for 36 days; v) a GSPE alone group (n=16) that received 200 mg/kg/day GSPE only for 60 consecutive days. Following drug treatments, the mortality rate and seizure stages of the animals were recorded. Six rats per treatment group were tested in the Morris water maze (MWM) and were then sacrificed. The sections of the hippocampus were divided into 2 parts for the determination of oxidative stress and the measurement of gene expression of pro-apoptotic proteins by western blot analysis (n=6/group). The remaining rats in each group were sacrificed and hippocampal tissue was processed for Nissl staining (n=3/group), the ultrastructural analysis of the mitochondria by transmission electron microscopy (n=3/group) or assays of mitochondrial ROS generation and the degree of mitochondrial swelling (n=4/group).

Behavioral assessment. The animals were observed for 1 h after each PTZ administration for changes in the seizure stage, which was assessed using the Racine scale: stage 0: no response; stage 1: hyperactivity, vibrissaes twitching; stage 2: head nodding, clonus and myoclonic jerks of the head; stage 3: unilateral forelimb clonus; stage 4: rearing with bilateral forelimb clonus; stage 5: the generalized tonic-clonic seizure with loss of writing reflex.

Behavioral screening. For behavioral screening, some rats (n=6/group) were tested in the MWM following the protocols previously described (37). The MWM consisted of a circular water tank (180 cm in diameter, 70 cm in height) filled with 22±1°C water. The pool was divided into 4 equal quadrants labeled N, W, S and E. A colorless escape platform (10 cm in diameter) was submerged 2 cm below the surface. Training was performed in 2 sessions daily for 5 days with an inter-session interval of 2 h. Each session consisted of 4 trials with an inter-trial interval of 30 sec. In each trial, the rat was gently placed in a randomly selected quadrant with its nose pointing toward the wall and allowed to find the escape platform. If a rat failed to find the platform within 120 sec, the escape latency was recorded as 120 sec and the rat was placed on the platform. The rats remained on the platform for 10 sec before the start of the next trial. On the 6th day, a probe trial of spatial memory was conducted by removing the platform and measuring both the time spent in the target quadrant and the number of crossings over the former platform location. The MWM was conducted between 9:00 a.m. and 18:00 p.m. to minimize performance variations due to circadian rhythmicity.

Nissl staining. Fifteen animals (n=3/group) were decapitated and a 5-mm-thick coronal section, including the bilateral hippocampus, was excised from the brains. The sections were fixed in 4% paraformaldehyde for 24 h, dehydrated in alcohol, cleared with xylene and embedded in paraffin. The paraffin-embedded brain sections were sliced at 5 µm thickness and Nissl-stained with 1% thionin. In every 5th slice (3 slices per animal), we counted the number of surviving
Results

Behavioral assessment. The injection of PTZ alone for 36 consecutive days caused significant mortality (27.3%), which was reduced by pre-treatment with 100 mg/kg GSPE (11.1%) and 200 mg/kg GSPE (5.6%). No fatalities occurred in the control group or the 200 mg/kg GSPE group, indicating that this high dosage has little or no inherent toxicity. As shown in Fig. 1, there was no seizure behavior in the control group and the 200 mg/kg GSPE group. On the other hand, severe epileptic seizures were induced by the kindling injections of PTZ for
36 days, and the PTZ group had epileptic seizures earlier than the other groups, while high-dose GSPE pre-treatment (200 mg/kg) significantly delayed the time to seizure. Although the rats in the low-dose group (100 mg/kg) exhibited mildly delayed seizures, the difference was not significant compared to the PTZ group (P=0.71), suggesting that GSPE may partially suppress epileptic seizures.

GSPE reverses cognitive impairment following seizures. To determine whether GSPE alleviates PTZ-induced cognitive impairment, we tested spatial learning and memory in the MWM following drug treatments (Fig. 2). The rats from all the groups showed a progressive decline in the escape latency during training (Fig. 2A), and this decline was more significant as the training days progressed [F(1,25)=928.84, P<0.001] and drug treatment group [F(4,25)=13.469, P<0.001]. The rats in the PTZ alone group (35 mg/kg/d) exhibited significantly prolonged escape latencies during all sessions compared to the control rats (P<0.001), while pre-treatment with GSPE dose-dependently decreased escape latency compared to the PTZ group (P=0.021 at 100 mg/kg and P<0.001 at 200 mg/kg). Escape latencies did not differ significantly between the high-dose GSPE group and the control group (P=0.570), indicating the near complete reversal of the PTZ-induced spatial learning deficit. In the probe trial (Fig. 2B and C), the rats treated with the vehicle + PTZ crossed the platform location significantly fewer times than the controls [F(4,25)=30.223, P<0.001] and spent less time in the target (former platform) quadrant than
the control rats [F(4,25)=23.482, P<0.001]. The PTZ + GSPE groups also crossed the former platform location more often than the PTZ group and spent significantly more time in the target quadrant (P=0.045, P<0.001). Again, there was no significant difference in mean latency or the time in the target quadrant between the high-dose GSPE group and the control group (P=0.869, P=0.128), indicating the near complete reversal of the PTZ-induced spatial memory deficit.

GSPE rescues hippocampal CA1 neurons. Pyramidal neurons in the Nissl-stained sections from the control rats were evenly stained light blue and had regularly shaped cell bodies. By contrast, morphological abnormalities, including blurred caryotheca and pyknotic nuclei were apparent in sections from PTZ group rats. The average density of intact surviving neurons was lower in the PTZ group compared to the control group, while pre-treatment with GSPE reversed the damage to cell morphology (Fig. 3) and reversed the decline in CA1 pyramidal cell density (Fig. 4). Compared to the PTZ group, the number of damaged neurons was significantly and dose-dependently reduced by GSPE pre-treatment (P<0.05 for both low and high doses). The GSPE alone group showed comparable cell density to the control group, underscoring the low or absent neurotoxicity of the extract (P=0.254).

GSPE preserves mitochondrial ultrastructure during seizures. To demonstrate the effects of GSPE pre-treatment on the mitochondria, the morphology of the mitochondria was further observed. Compared to the control group, obvious morphological changes were observed in the mitochondria from the PTZ group, such as damaged membranes and obscure boundaries, whereas GSPE pre-treatment partly reversed these changes (Fig. 5).

GSPE reduces MDA accumulation and upregulates GSH levels. As shown in Fig. 6A and B, there were significant group differences in both hippocampal MDA accumulation and GSH levels [F(4,25)=178.732, F(4,25)=518.96, P<0.001]. Compared to the control group, the accumulation of MDA was significantly higher (P<0.001) and GSH levels were lower in the PTZ group (P<0.001). Pre-treatment with GSPE dose-dependently reduced MDA and upregulated GSH levels compared to the PTZ group. Therefore, GSPE pre-treatment partially alleviated the oxidative stress induced by PTZ-induced seizures, although MDA levels were still higher and GSH levels still lower than the control group (P<0.05, P<0.05). There were no significant differences between the GSPE alone group and the control group (P=0.035, P=0.393).

GSPE suppresses PTZ-induced mitochondrial ROS production and degree of mitochondrial swelling. As shown in Fig. 6C, mitochondrial ROS generation was significantly higher in the

Figure 4. Effect of grape seed proanthocyanidin extract (GSPE) pre-treatment on the quantity of Nissl-positive CA1 pyramidal neurons in the hippocampus. The number of surviving pyramidal cells was counted under a light microscope and expressed as cells per mm linear length of the rat CA1 subfield. Data are shown as the means ± SEM. *P<0.05 compared to the control (CON) group; #P<0.05 compared to the pentylenetetrazole (PTZ) group.

Figure 5. Pre-treatment with grape seed proanthocyanidin extract (GSPE) reverses pentylenetetrazole (PTZ)-induced ultrastructural damage to mitochondria. Photomicrographs (magnification x40,000) showing mitochondrial ultrastructure in the CA1 area of the hippocampus. (A) Control group; (B) PTZ group; (C) PTZ + 100 mg/kg GSPE group; (D) PTZ + 200 mg/kg GSPE group; (E) GSPE alone group. In (B), a mitochondrial vacuole is indicated by a thin black arrow and one damaged mitochondria by a thick black arrow. In the PTZ group, mitochondria ridge disorder and vacuoles were commonly observed. These abnormal changes were reversed by GSPE pre-treatment (C and D). n=3/group.
PTZ group than the control group \([F(4,15)=66.308, P<0.001]\), whereas pre-treatment with GSPE dose-dependently decreased mitochondrial ROS production compared to the PTZ group \((P=0.001, P=0.003)\). Thus, GSPE partially suppressed mitochondrial ROS production in the hippocampus, although ROS levels were still higher than those in the control group. There was no significant difference in mitochondrial ROS production between the GSPE alone and control groups \((P=0.18)\). Accordingly, mitochondrial swelling in the isolated brain mitochondria was monitored by measuring the change in absorbance of the suspension at 520 nm. As shown in Fig. 6D, the degree of mitochondrial swelling was significantly increased by 42.98% \((P<0.001)\) in the PTZ group compared to the control group. Compared with the PTZ group, GSPE pre-treatment dose-dependently inhibited mitochondrial swelling by 29.8 and 14.4% \((P<0.05\) for both doses), respectively.

**GSPE inhibits mitochondrial Cyt c release induced by seizures.** The translocation of mitochondrial Cyt c to the cytosol induces the formation of the apoptosomes, leading to apoptotic death. As shown in Fig. 7, there was a significant group difference in the level of cytosolic Cyt c \([F(4,25)=141.021, P<0.001]\) and mitochondrial Cyt c \([F(4,25)=234.398, P<0.001]\). Compared to the control group, the cytoplasmic Cyt c concentration was markedly higher and the mitochondrial Cyt c concentration was markedly lower in the PTZ group \((P<0.001, P<0.001)\), while pre-treatment with GSPE dose-dependently reversed those levels compared to the PTZ group \((P<0.05\) for both treatments).
doses), There was no significant difference between the GSPE alone and control groups (P=0.096, P=0.632), indicating that high-dose GSPE has no endogenous pro-apoptotic activity.

**GSPE suppresses the PTZ-induced increase of in caspase-9 and caspase-3 expression.** Caspase-3 is the principle effector of the mitochondrial-dependent apoptotic pathway and is activated during seizure-induced neuronal death (36). Western blot analysis revealed a significant group difference in both activated caspase-9 and caspase-3 expression in the hippocampus [F(4,25)=554.387, P<0.001; F(4,25)=347.38, P<0.001]. Compared to the control group, activated caspase-9 and caspase-3 levels were significantly higher in the PTZ group (P<0.001, P<0.001), while pre-treatment with GSPE significantly decreased these levels compared to the PTZ group (P<0.001, P<0.001) (Fig. 7).

**Discussion**

Although numerous advances have been made in the diagnosis and treatment of epilepsy, the precise pathogenic mechanism is obscure in the majority of patients, hampering effective treatment. In our study, GSPE pre-treatment partially suppressed seizures and reduced the PTZ-induced mortality rate. Of note, PTZ-induced kindling caused marked cognitive impairment as measured in the MWM, which is in agreement with our previous report (37), while GSPE pre-treatment had significant nootropic and neuroprotective effects, likely mediated by reduced oxidative stress and the rescue of mitochondrial function.

Chronic kindling by repeated chemical convulsant administration or electrical stimulation is among the most widely used models of chronic epilepsy for studies on epileptogenesis, novel drug targets, and treatment and preventative strategies (38). The underlying mechanisms of seizure pathogenesis have been proven to be complex and are not completely understood; several other molecular mechanisms are involved, including oxidative stress, inflammation, glutamate excitotoxicity and calcium overload. This is consistent with our results that GSPE pre-treatment partially suppressed, but not completely eliminated epileptic seizures. Moreover, in light of studies demonstrating that GSPE protects against oxidative stress (39) and enhances the working memory and cognitive performance in a rat model of Alzheimer's disease (30), we primarily assessed the effects against epilepsy-associated oxidative stress and cognitive decline. As expected, PTZ-induced kindling caused an obvious increase in escape latency in MWM learning sessions and a marked decrease in time spent in the target quadrant during the probe (memory) trial. By contrast, pre-treatment with GSPE prior to PTZ significantly improved spatial learning and memory, as manifested by shorter escape latencies in learning sessions and longer time spent in the target quadrant during the probe trial. These results are consistent with those of a previous study (30).

Oxidative stress may be a critical pathogenic mechanism in the development of chronic epilepsy. Oxidative stress can be self-propagating in that initial oxidative damage creates additional free radicals, damages antioxidant enzymes, depletes antioxidant molecules, such as GSH and damages mitochondria, producing more ROS (11,40). Indeed, PTZ-induced seizures increased lipid peroxidation (MDA accumulation), decreased GSH in the hippocampus and enhanced ROS production in the mitochondria isolated from the epileptic hippocampus, implicating the exacerbation of oxidative stress in epileptic kindling (41). All these effects were partially or completely reversed by GSPE pre-treatment.

Mitochondria are the primary site of ROS production. Free radicals are highly reactive and thus damage biomolecules close to the site of generation, making mitochondria uniquely vulnerable to macromolecule dysfunction and DNA damage (12). Mitochondrial dysfunction and the overproduction of ROS may also enhance neuronal excitability and increase seizure susceptibility (42). Mitochondrial dysfunction is a common trigger for apoptosis, as ROS damage can induce Cyt c release and sequential activation of pro-apoptotic caspase-9 and caspase-3 (43,44). Therefore, synthetic antioxidants that protect mitochondrial targets and decrease neuronal death may be useful supplements for the clinical management of patients with seizures (45). Our results revealed that pre-treatment with GSPE decreased PTZ-induced mitochondrial ROS production and the degree of swelling and partially suppressed neuronal apoptosis, possibly through the protection of mitochondrial function and the inhibition of Cyt c translocation and caspase activation (46,47).

In order to further confirm the molecular change in the mitochondria that is responsible for the protective effects of GSPE pre-treatment, we focused on morphological observation. The findings from Nissl staining were consistent with the molecular results. Western blot analysis demonstrated that PTZ-induced seizures significantly increased the hippocampal expression of active caspase-3 and the release of cytosolic Cyt c; Nissl staining indicated significant pyramidal cell loss with ultrastructural signs of apoptosis. Furthermore, electron microscopy indicated that the mitochondria were damaged in the PTZ group, while GSPE pre-treatment reversed these morphological changes. Considering all of the above, targeting mitochondrial bioenergetics and oxidative stress with GSPE and non-pharmacological treatments may prove to be useful for the management of epilepsy (12).

In conclusion, GSPE, a safe and affordable intervention for clinical use, was effective in attenuating oxidative stress in the hippocampus of rats with chronic seizures. More importantly, pre-treatment with GSPE improved cognitive decline, at least in part, by protecting mitochondrial function and suppressing caspase-3-dependent apoptosis. However, due to the complex mechanisms of epilepsy, further studies are required to define the optimal treatment protocols and identify additional molecular targets of GSPE in epilepsy.

**Acknowledgements**

The authors are cordially indebted to the Natural Science Foundation of Hebei Province, China (C2010000548) for its financial support. We sincerely thank Ruichun Liu, Dongxia Wu, Shuyu Wu and Hongran Wu for providing valuable suggestions and technical assistance.

**References**

1. Bertram EH: Temporal lobe epilepsy: where do the seizures really begin. Epilepsy Behav 14 (Suppl 1): 32-37, 2009.
2. Kernan CL, Asarnow R, Siddarth P, et al: Neurocognitive profiles in children with epilepsy. Epilepsia 53: 2156-2163, 2012.
3. Henshall DC and Simon RP: Epilepsy and apotaxis pathways. J Cereb Blood Flow Metab 25: 1557-1572, 2005.
4. Hermann B: Cognition in epilepsy and its transient impairment. Epilepsy Behav 22: 419, 2011.
5. Sudha K, Rao AV and Rao A: Oxidative stress and antioxidants in epilepsy. Clin Chim Acta 303: 19-24, 2001.
6. Liu H, Zhang X, Du Y, et al: Leomarine protects brain injury by increased activities of UCP4, SOD, CAT and Bel-2, decreased levels of MDA and Bax, and ameliorated ultrastructure of mitochondria in experimental stroke. Brain Res 1474: 73-81, 2012.
7. Colle D, Santos DB, Moreira EL, et al: Probuloc increases striatal glutathione peroxidase activity and protects against 3-nitropro-pionic acid-induced pro-oxidative damage in rats. PLoS One 8: e65683, 2013.
8. Sevin G, Ozsorak-Sozger G, Keles D, et al: Taurine inhibits increased MMP-2 expression in a model of oxidative stress induced by glutathione depletion in rabbit heart. Eur J Pharmacol 706: 98-106, 2013.
9. Yabuki Y and Fukunaga K: Oral administration of glutathione improves memory deficits following transient brain ischemia by reducing brain oxidative stress. Neuroscience 250: 394-407, 2013.
10. Dillioeglul MO, Kir HM, Demir C, et al: Effect of pentylenetetrazole and sound stimulation induced single and repeated convulsive seizures on the MDA, GSH and NO levels, and SOD activities in rat liver and kidney tissues. Brain Res Bull 83: 356-359, 2010.
11. Melha J, Reeta KH, Gupta P and Gupta YK: Protective effect of curcumin against seizures and cognitive impairment in a pentylenetetrazole-kindled epileptic rat model. Life Sci 87: 596-603, 2010.
12. Waldbaum S and Patel M: Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res 88: 23-45, 2010.
13. Borniquel S, Valle I, Cadenas S, Lamas S and Monsalve M: Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha. FASEB J 20: 1889-1899, 2006.
14. Fariss MW, Chan CB, Patel M, Van Houten B and Orrenius S: Nitric oxide regulates mitochondrial oxidative stress protection in animal tissues by thiobarbituric acid reaction. Anal Biochem 706: 383-397, 2003.
15. Xie T, Wang WP, Jia LI, et al: Environmental enrichment restores cognitive deficits induced by prenatal maternal seizure. Brain Res 1470: 80-88, 2012.
16. Okhawa H, Ohishi N and Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1979.
17. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77, 1959.
18. He XL, Wang YH, Gao M, Li XX, Zhang TT and Du GH: Baicalein protects rat brain mitochondria against chronic cerebral hyperperfusion-oxidative induced oxidative damage. Brain Res 1249: 212-221, 2009.
19. Rupinder SK, Gurpreet AK and Manjeet S: Cell suicide and caspases. Vascul Pharmacol 46: 383-393, 2007.
20. Xie T, Wang WP, Mao ZF, et al: Effects of epigallocatechin-3-gallate on pentylenetetrazole-induced kindling, cognitive impairment and oxidative stress in rats. Neurosci Lett 516: 237-241, 2012.
21. Tourova A, Ferri R, Del Gracco S, Elia M, Musumeci SA and Stefanini MC: Spike morphology in PTZ-induced generalized and coxib-induced partial experimental epilepsy. Funct Neurol 11: 237-245, 1996.
22. Al-Malki AL, Sayed AA and El Rabey HA: Proanthocyanidin attenuation of oxidative stress and NF-xB protects apolipoprotein E-deficient mice against diabetic nephropathy. Evid Based Complement Alternat Med 2013: 769409, 2013.
23. Sayre LM, Perry G and Smith MA: Oxidative stress and neurodegeneration. Chem Res Toxicol 21: 172-188, 2008.
24. Freitas RM: Investigation of oxidative stress involvement in hippocampus in epilepsy model induced by pilocarpine. Neurosci Lett 462: 225-229, 2009.
25. Heimann M, Buchheim K, Gabriel S, Kann O, Kovacs R and Schuchmann S: Cell death and metabolic activity during epileptiform discharges and status epilepticus in the hippocampus. Prog Brain Res 135: 197-210, 2002.
26. Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS and Liu LS: PCSK9 siRNA inhibits HUV/EC apoptosis induced by ox-LDL via Bel-2/Bax-caspase9-caspase3 pathway. Mol Cell Biochem 359: 347-358, 2012.
27. Hong GL, Liu JM, Zhao GJ, et al: The reversal of paraquat-induced mitochondria-mediated apoptosis by cycloartenol, the important role of Nrf2 pathway. Exp Cell Res 316: 471-480, 2010.
28. Hatori M, Kojima M, Goh P, et al: Brain mitochondria are a major source of reactive oxygen species during seizures. Proc Natl Acad Sci 108: 7797-7802, 2011.
29. Lonardi S, Neri C, Risotta R, et al: Protective function of nico-tinamide against ketamine-induced apoptotic neurodegeneration in the infant rat brain. J Mol Neurosci 47: 67-75, 2012.
30. Cheng M, Gao HQ, Xu L, Li BY, Zhang H and Li XH: Cardioprotective effects of grape seed proanthocyanidins in streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 50: 503-509, 2007.
31. Li J, Liu H, Ramachandran S, et al: Grape seed proanthocy-anidins ameliorate Doxorubicin-induced cardiotoxicity. Am J Chin Med 38: 569-584, 2010.